Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Sumitomo takes out Urovant, and Myovant beckons
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
Another strong year for novel drug approvals is in the making
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.
Obseva shows why red flags are worth heeding
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
